Saatja: "Ellen Lurje" <
[email protected]>
Saaja:
[email protected]
Teema: Vs: Compassionate use programs
Kuupäev: 2024-05-18 05:34
Dear Beatrice,
Thank you for contacting us!
Yes, we have a paragraph in our legislation:
§ 21. Authorisation for distribution of unauthorised medicinal product
(7) In the absence of authorised medicinal products with equivalent effect
or where such products are not distributed according to treatment needs, the
State Agency of Medicines may, in addition to the provisions of subsection 1
of this section, grant an authorisation for distribution of:
4) medicinal products offered free of charge by the manufacturer of
medicinal products provided that the doctor providing treatment to the
patient has confirmed that the medicinal product is necessary for
life-saving purposes and there are no other options for the treatment of a
chronic or life-threatening illness and also provided that the illness is
deemed life-threatening and all other treatment methods for which the
payment obligation is assumed by the Estonian Health Insurance Fund and that
are medically suitable and financially accessible to the person have been
exhausted, and it is likely that the benefits of the medicinal product
outweigh possible risks.
https://www.riigiteataja.ee/en/eli/ee/Riigikogu/act/519012024002/consolide
To use a medicinal product via CUP, the program has to match the criteria
stated for CUP, however it is named by the company (expanded access, early
access, etc).
In European legislation named patient prescription usually refers to using
unauthorised medicines but not under CUP circumstances (for example when
there are shortages or an authorised medicine is not distributes in a
particular country etc) (Article 5 of Directive 2001/83/EC1).
I hope this answered your questions, if not, let me know!
Kind regards,
Ellen Lurje
Specialist
Bureau of Clinical Assessment
Department Marketing Authorisations
State Agency of Medicines
<mailto:
[email protected]>
[email protected]
1 Nooruse Street
50411 Tartu
Estonia
Phone: +372 737 4140
<http://www.ravimiamet.ee/> www.ravimiamet.ee
Selles e-kirjas sisalduv teave (kaasa arvatud manused) on mõeldud
ametialaseks kasutamiseks ning seda võivad kasutada vaid e-kirja
adressaadid. E-kirjas sisalduvat teavet ei tohi ilma saatja selgelt
väljendatud loata edasi saata ega mis tahes viisil kolmandatele isikutele
avaldada. Juhul, kui Te olete saanud käesoleva e-kirja eksituse tõttu,
teavitage sellest koheselt saatjat ning kustutage e-kiri.
This e-mail and any attachments transmitted may contain confidential and
privileged information. If you are not the intended recipient, please
notify the sender immediately by returning the e-mail and permanently
deleting what you have recieved. Any dissemination or use of this
information by a third person without permission is prohibited and may be
illegal.
From: BEATRICE - ELENA LASCU <
[email protected]
<mailto:
[email protected]> >
Sent: neljapäev, 16. mai 2024 15:59
To: BEATRICE - ELENA LASCU <
[email protected]
<mailto:
[email protected]> >
Subject: Compassionate use programs
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu
saatja korral palume linke ja faile mitte avada.
Dear Sir/ Madam,
could you help me with an explanation of how Article 83 of Regulation (EC)
No 726/2004 applies in your country? Could you help me with a legislative
article?
In addition, is there a distinction made between CUP (compassionate use
program), NPP (name patient prescription), or EAP (expanded access program)?
Thank you in advance for your help!
Beatrice Lascu, RPh